Offshoring labor to countries with cheaper labor and relaxed regulatory schemes has devastated industries such as textiles and manufacturing – and stands to do the same for much of biotechnology R&D. Read this essential series of articles to learn more about the potential and impacts of offshoring in biotechnology, and way to deal with this inevitability.
The biotech sector saw a significant run-up last month, but for at least one analyst, questions remain about what the second half holds.
The health ministry has decided to set up an autonomous drug control authority on the lines of the US Food and Drugs Administration, but with a mandate going far beyond the latter.
The United States appears to be a relatively hospitable place for embryonic stem cell research, especially compared to Canada and some nations in Europe where governments not only refuse financial support for human cloning to produce stem cells, they outlaw the practice.
The editor-in-chief of the New England Journal of Medicine accused three of the largest drug companies of ‘making a mockery‘ of efforts to create transparency in clinical trials, adding that could lead some important medical publications to avoid publishing their studies.
With a closely divided House poised to vote today on whether to expand federal funding of human embryonic stem cell research, opponents are offering fence-sitters what they say is an embryo-friendly alternative: a bill that would foster the use of stem cells from umbilical cords discarded after birth.
The U.S. government is dangling a big carrot — and some wheat and corn — to encourage manufacturers to make more products from biobased materials.
How does Genentech do it? The biotech company focuses on science — not marketing, acquisitions, or patents